The proteomics market grew from $1.1 billion in 2001 to almost $1.4 billion in 2002 and, based on first quarter numbers, the growth rate is continuing in 2003. But the success is creating a bottleneck. High-throughput and/or high-output technologies are used to discover potential biomarkers and drug targets, but the validation methods are low-throughput and low-output. For proteomics to continue its current growth rate, the industry needs new methods and technologies to speed validation. Fortunately, multiple emerging technologies are poised to meet this need.
The report, Proteomics 2003, presents detailed interviews with proteomics experts, thorough evaluations of 75 leading proteomics companies in the United States and Europe, three scenarios for the future of the industry, and a quantitative market model. The analysis is based on extensive research that includes dozens of interviews with current and potential customers and with company representatives.
View Cart
